A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy

Sheng Li, En Kimura, Rainer Ng, Brent M. Fall, Leonard Meuse, Morayma Reyes Gil, John A. Faulkner, Jeffrey S. Chamberlain

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

A promising approach for treating Duchenne muscular dystrophy (DMD) is by autologous cell transplantation of myogenic stem cells transduced with a therapeutic expression cassette. Development of this method has been hampered by a low frequency of cellular engraftment, the difficulty of tracing transplanted cells, the rapid loss of autologous cells carrying marker genes that are unable to halt muscle necrosis and the difficulty of stable transfer of a large dystrophin gene into myogenic stem cells. We engineered a 5.7 miniDys-GFP fusion gene by replacing the dystrophin C-terminal domain (ΔCT) with an eGFP coding sequence and removing much of the dystrophin central rod domain (ΔH2-R19). In a transgenic mdx4Cvmouse expressing the miniDys-GFP fusion protein under the control of a skeletal muscle-specific promoter, the green fusion protein localized on the sarcolemma, where it assembled the dystrophin-glycoprotein complex and completely prevented the development of dystrophy in transgenic mdx4Cv muscles. When myogenic and other stem cells from these mice were transplanted into mdx4Cv recipients, donor cells can be readily identified in skeletal muscle by direct green fluorescence or by using antibodies against GFP or dystrophin. In mdx4Cv mice reconstituted with bone marrow cells from the transgenic mice, we monitored engraftment in various muscle groups and found the number of miniDys-GFP+ fibers increased with time. We suggest that these transgenic mdx 4Cv mice are highly useful for developing autologous cell therapies for DMD.

Original languageEnglish (US)
Pages (from-to)1610-1622
Number of pages13
JournalHuman Molecular Genetics
Volume15
Issue number10
DOIs
StatePublished - May 15 2006
Externally publishedYes

Fingerprint

Dystrophin
Duchenne Muscular Dystrophy
Gene Fusion
Cell- and Tissue-Based Therapy
Genetic Therapy
Stem Cells
Muscles
Transgenic Mice
Skeletal Muscle
Inbred mdx Mouse
Sarcolemma
Autologous Transplantation
Cell Transplantation
Bone Marrow Cells
Genes
Glycoproteins
Proteins
Necrosis
Fluorescence
Antibodies

ASJC Scopus subject areas

  • Genetics

Cite this

A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. / Li, Sheng; Kimura, En; Ng, Rainer; Fall, Brent M.; Meuse, Leonard; Reyes Gil, Morayma; Faulkner, John A.; Chamberlain, Jeffrey S.

In: Human Molecular Genetics, Vol. 15, No. 10, 15.05.2006, p. 1610-1622.

Research output: Contribution to journalArticle

Li, Sheng ; Kimura, En ; Ng, Rainer ; Fall, Brent M. ; Meuse, Leonard ; Reyes Gil, Morayma ; Faulkner, John A. ; Chamberlain, Jeffrey S. / A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. In: Human Molecular Genetics. 2006 ; Vol. 15, No. 10. pp. 1610-1622.
@article{86717a8853734ccdb61f6638b9e83a1f,
title = "A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy",
abstract = "A promising approach for treating Duchenne muscular dystrophy (DMD) is by autologous cell transplantation of myogenic stem cells transduced with a therapeutic expression cassette. Development of this method has been hampered by a low frequency of cellular engraftment, the difficulty of tracing transplanted cells, the rapid loss of autologous cells carrying marker genes that are unable to halt muscle necrosis and the difficulty of stable transfer of a large dystrophin gene into myogenic stem cells. We engineered a 5.7 miniDys-GFP fusion gene by replacing the dystrophin C-terminal domain (ΔCT) with an eGFP coding sequence and removing much of the dystrophin central rod domain (ΔH2-R19). In a transgenic mdx4Cvmouse expressing the miniDys-GFP fusion protein under the control of a skeletal muscle-specific promoter, the green fusion protein localized on the sarcolemma, where it assembled the dystrophin-glycoprotein complex and completely prevented the development of dystrophy in transgenic mdx4Cv muscles. When myogenic and other stem cells from these mice were transplanted into mdx4Cv recipients, donor cells can be readily identified in skeletal muscle by direct green fluorescence or by using antibodies against GFP or dystrophin. In mdx4Cv mice reconstituted with bone marrow cells from the transgenic mice, we monitored engraftment in various muscle groups and found the number of miniDys-GFP+ fibers increased with time. We suggest that these transgenic mdx 4Cv mice are highly useful for developing autologous cell therapies for DMD.",
author = "Sheng Li and En Kimura and Rainer Ng and Fall, {Brent M.} and Leonard Meuse and {Reyes Gil}, Morayma and Faulkner, {John A.} and Chamberlain, {Jeffrey S.}",
year = "2006",
month = "5",
day = "15",
doi = "10.1093/hmg/ddl082",
language = "English (US)",
volume = "15",
pages = "1610--1622",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy

AU - Li, Sheng

AU - Kimura, En

AU - Ng, Rainer

AU - Fall, Brent M.

AU - Meuse, Leonard

AU - Reyes Gil, Morayma

AU - Faulkner, John A.

AU - Chamberlain, Jeffrey S.

PY - 2006/5/15

Y1 - 2006/5/15

N2 - A promising approach for treating Duchenne muscular dystrophy (DMD) is by autologous cell transplantation of myogenic stem cells transduced with a therapeutic expression cassette. Development of this method has been hampered by a low frequency of cellular engraftment, the difficulty of tracing transplanted cells, the rapid loss of autologous cells carrying marker genes that are unable to halt muscle necrosis and the difficulty of stable transfer of a large dystrophin gene into myogenic stem cells. We engineered a 5.7 miniDys-GFP fusion gene by replacing the dystrophin C-terminal domain (ΔCT) with an eGFP coding sequence and removing much of the dystrophin central rod domain (ΔH2-R19). In a transgenic mdx4Cvmouse expressing the miniDys-GFP fusion protein under the control of a skeletal muscle-specific promoter, the green fusion protein localized on the sarcolemma, where it assembled the dystrophin-glycoprotein complex and completely prevented the development of dystrophy in transgenic mdx4Cv muscles. When myogenic and other stem cells from these mice were transplanted into mdx4Cv recipients, donor cells can be readily identified in skeletal muscle by direct green fluorescence or by using antibodies against GFP or dystrophin. In mdx4Cv mice reconstituted with bone marrow cells from the transgenic mice, we monitored engraftment in various muscle groups and found the number of miniDys-GFP+ fibers increased with time. We suggest that these transgenic mdx 4Cv mice are highly useful for developing autologous cell therapies for DMD.

AB - A promising approach for treating Duchenne muscular dystrophy (DMD) is by autologous cell transplantation of myogenic stem cells transduced with a therapeutic expression cassette. Development of this method has been hampered by a low frequency of cellular engraftment, the difficulty of tracing transplanted cells, the rapid loss of autologous cells carrying marker genes that are unable to halt muscle necrosis and the difficulty of stable transfer of a large dystrophin gene into myogenic stem cells. We engineered a 5.7 miniDys-GFP fusion gene by replacing the dystrophin C-terminal domain (ΔCT) with an eGFP coding sequence and removing much of the dystrophin central rod domain (ΔH2-R19). In a transgenic mdx4Cvmouse expressing the miniDys-GFP fusion protein under the control of a skeletal muscle-specific promoter, the green fusion protein localized on the sarcolemma, where it assembled the dystrophin-glycoprotein complex and completely prevented the development of dystrophy in transgenic mdx4Cv muscles. When myogenic and other stem cells from these mice were transplanted into mdx4Cv recipients, donor cells can be readily identified in skeletal muscle by direct green fluorescence or by using antibodies against GFP or dystrophin. In mdx4Cv mice reconstituted with bone marrow cells from the transgenic mice, we monitored engraftment in various muscle groups and found the number of miniDys-GFP+ fibers increased with time. We suggest that these transgenic mdx 4Cv mice are highly useful for developing autologous cell therapies for DMD.

UR - http://www.scopus.com/inward/record.url?scp=33745191588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745191588&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddl082

DO - 10.1093/hmg/ddl082

M3 - Article

C2 - 16595609

AN - SCOPUS:33745191588

VL - 15

SP - 1610

EP - 1622

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 10

ER -